From: Early prediction of pathologic response to neoadjuvant treatment of breast cancer: use of a cell-loss metric based on serum thymidine kinase 1 and tumour volume
Pathologic status
Quartile 1
Quartile 2
Quartile 3
Quartile 4
n (%)
pCR*
3 (11.5)
6 (23.1)
12 (46.2)
pT1
7 (26.9)
11 (42.3)
13 (50.0)
pT2 + pT3
16 (61.5)